A review of the costs associated with depression and treatment noncompliance: the potential benefits of online support

Abstract

This systematic review examines the economic and human costs of depression and the potential savings associated with improvement in patient adherence to treatment with antidepressants through the use of enhanced-care programs. A MEDLINE search was conducted for papers published on the health economics and costs of depression and compliance, adherence, and persistence. Compliance data collected through the online antidepressant compliance support website iCAN (www.ican.co.uk) were compared with data for patients with depression from the IMS Disease Analyzer UK database. Depression frequently causes unemployment, absenteeism, and presenteeism, which results in significantly reduced productivity. Indirect costs of depression accounted for more than $50 billion, whereas direct costs resulted in expenditure of $26 billion, in the US in 2000. Improving patients' compliance with their antidepressant medication results in improved outcomes and prolongs remission from depression, increasing work productivity, and thus reducing overall costs. The implementation of remote enhanced-care programs may improve compliance and reduce overall costs. Novel methods for delivering enhanced-care programs to assist in maintaining compliance have the potential to further reduce costs and should be a focus of future research. In conclusion, depression is a common disorder with a high economic impact. Enhanced-care programs may lower costs associated with depression and improve patients' lives.

Evaluation of a pharmacist intervention on patients initiating pharmacological treatment for depression: A randomized controlled superiority trial

“…Depressive disorders are associated with considerable disability (Mathers and Loncar 2006) and with increased suicide rates (Angst et al 1999). This results in a high burden for patients and society and is costly to the system, mainly due to patients' inability to work (Salvador-Carulla et al 2011;Wade and Haring 2010).…”

Transdermal Estradiol Treatment for Postpartum Depression

“…Ovarian function was sufficiently suppressed in obese women to provide contraception; however, the pharmacodynamic target in our study was PPMD, which may require higher E2 concentrations. Finally, noncompliance is associated with poverty and obesity [45] and depression [46], and may have contributed to low serum concentrations or patch failure (despite claims of adhesion).…”

Avaliação da qualidade de vida de sobreviventes de leucemia na infância

“…Estudos sobre abordagens não presenciais, na forma de contatos online ou follow-up telefônico de pacientes, têm demonstrado bons resultados para o tratamento de pacientes em diversas clínicas médicas, como por exemplo, para estimular um aumento da adesão à terapêutica proposta ou para acompanhar os impactos psicossociais de pacientes submetidas a procedimentos cirúrgicos radicais para tratamento de câncer ginecológico (Robertson, Smith, & Tannenbaum, 2005;Wade & Haring, 2010;Carter et al, 2004).…”